Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: A therapeutic opportunity?

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 3, 2010, Pages 325-330

  Calvo, A ^a   Moglia, C ^a   Balma, M ^a   Chio A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Immunity; Immunotherapy; Innate immunity

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOPHOSPHAMIDE; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1 ANTIBODY; GLATIRAMER; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MINOCYCLINE; RECOMBINANT BETA INTERFERON; VOLTAGE GATED CALCIUM CHANNEL;

ADAPTIVE IMMUNITY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; AUTOIMMUNITY; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; LIQUORPHERESIS; LYMPH NODE IRRADIATION; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; PRIMARY LATERAL SCLEROSIS; PROGRESSIVE BULBAR PALSY; PROGRESSIVE MUSCULAR ATROPHY;

EID: 77954345809     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710791292657     Document Type: Article

References (46)

1. Latov, N.; Hays, AP.; Donofrio, P.D.; Liao, J.; Ito, H.; McGinnis, S.; Konstadoulakis, M.; Freddo, L.; Shy, M.E.; Sherman, W.H.; Chang, H.W.; Greenberg, H.S.; Albers, J.W.; Alessi, A.G.; Keren, D.; Yu, R.K.; Rowland, L.P.; Kabat, E.A. Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology, 1988, 38(5), 763-768.
2. Pestronk, A.; Lopate, G.; Kornberg, A.J.; Elliot, J.L.; Blume, G.; Yee, W.C.; Goodnough, L.T. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology, 1994, 44(11), 2027-2031.
3. Dalaka, M.C.; Stein, D.P.; Otero, C.; Sekul, E.; Cupler, E.J.; McCrosky, S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol., 1994, 51(9), 861-864.
4. Mitsumoto, H.; Kumar, S.; Levin, K.H.; Shields, R.W.; Secic, M.; Wilbourn, A.J.; Desai, R.G. Intravenous immunoglobulin treatment in amyotrophic lateral sclerosis. Ann. Neurol., 1992, 32, 252.
5. Delbono, O.; Garcia, J.; Appel, S.H.; Stefani, E. IgG from amyotrophic lateral sclerosis affects tubular calcium channels of skeletal muscles. Am. J. Physiol., 1991, 260(6), C1347-C1351.
6. Smith, R.G.; Siklos, L.; Alexianu, M.E.; Engelhardt, J.I.; Mosier, D.R.; Colom, L.; Habib Mohamed, A.; Appel, S.H. Autoimmunity and ALS. Neurology, 1996, 47(4 Suppl 2), S40-S45.
7. Kawamata, T.; Akiyama, H.; Yamada, T.; McGeer, P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol., 1992, 140(3), 691-707.
8. Cleveland, J.L.; Ihle, J.N. Contenders in FasL/TNF death signaling. Cell, 1995, 81(4), 479-482.
9. Petri, S.; Kiaei, M.; Wille, E.; Calingasan, N.Y.; Flint Beal, M. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. J. Neurol. Sci., 2006, 251(1-2), 44-49.
10. La Bella, V.; Goodman, J.C.; Appel, S.H. Increased CSF glutamate following injection of ALS immunoglobulins. Neurology, 1997, 48(5), 1270-1272.
11. Engelhardt, J.I.; Appel, S.H.; Killian, J.M. Motor neuron destruction in guinea pigs immunized with bovine spinal cord ventral horn homogenate: experimental autoimmune gray matter disease. J. Neuroimmunol., 1990, 27(1), 21-31.
12. Engelhardt, J.I.; Tajti, J.; Appel, S.H. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol., 1993, 50(1), 30-36.
13. Obal, I.; Soos, J.; Jakab, K.; Siklos, L.; Engelhardt, J.I. Recruitment of activated microglia cells in the spinal cord of mice by ALS IgG. Neuroreport, 2001, 12(11), 2449-2452.
14. Latov, N. Plasma cell dyscrasia and motor neuron disease. Adv. Neurol., 1982, 36, 273-279.
15. Patten, B.M. Neuropathy and motor neuron syndromes associated with plasma cell disease. Acta Neurol. Scand., 1984, 70(1), 47-61.
16. Pestronk, A.; Adams, R.N.; Clawson, L.; Cornblath, D.; Kuncl, R.W.; Griffin, D.; Drachman, D.B. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology, 1988, 38(9), 1457-1461.
17. Kromberg, A.J. Anti-GM1 ganglioside antibodies: their role in the diagnosis and pathogenesis of immune-mediated motor neuropathies. J. Clin. Neurosci., 2000, 7(3), 191-194.
18. Bouche, P.; Le Forestier, N.; Maisonobe, T.; Fournier, E.; Willer, J.C. Electrophysiological diagnosis of motor neuron disease and pure motor neuropathy. J. Neurol. 1999, 246(7), 520-525.
19. Meucci, N.; Nobile-Orazio, E.; Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J. Neurol., 1996, 243, 117-120.
20. Drachman, D.B.; Chaudhry, V.; Cornblath, D.; Kuncl, R.W.; Pestronk, A.; Clawson, L.; Mellits, E.D.; Quaskey, S.; Quinn, T.; Calkins, A.; Order S. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Neurol., 1994, 35(2), 142-150.
21. Finsterer, J.; Mamoli, B. Liquorpheresis (CSF filtration) in familial amyotrophic lateral sclerosis. Spinal Cord, 1999, 37(8), 592-593.
22. Andrich, J. Short lasting improvement after treatment with cerebrospinal fluid filtration (CSFF) in two patients with sporadic amyotrophic lateral sclerosis (SALS). J. Neurol., 1996, 1243(Suppl 2), S95.
23. Nguyen, M.D.; D'Aigle, T.; Gowing, G.; Julien, J.P.; Rivest, S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004, 24(6), 1340-1349.
24. Raivich, G. Like cops on the beat: the active role of resting microglia. Trends Neurosci., 2005 28(11), 571-573.
25. Perry, V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun., 2004, 18(5), 407-413.
26. Henkel, J.S.; Engelhardt, J.I.; Siklos, L.; Simpson, E.P.; Kim, S.H.; Pan, T.; Goodman, J.C.; Siddique, T.; Beers, D.R.; Appel, S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol., 2004, 55 (2), 221-235.
27. Moisse, K.; Strong, M.J. Innate immunity in amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 2006, 1762(11-12), 1083-1093.
28. Liu, Y.; Hao, W.; Dawson, A; Liu, S.; Fassbender, K. Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J. Biol. Chem., 2009, 284(6), 3691-3699.
29. Hall, E.D.; Oostveen, J.A.; Gurney, M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial als. Glia, 1998, 23(3), 249-256.
30. Streit, W.J.; Conde, J.R.; Fendrick, S.E.; Flanary, B.E.; Mariani, C.L. Role of microglia in the central nervous system's immune response. Neurol. Res. 2005, 27(7), 685-691.
31. McGeer, P.L.; Itagaki, S.; McGeer, E.G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol., 1988, 76(6), 550-557.
32. Chiu, I.M.; Chen, A.; Zheng, Y.; Kosaras, B.; Tsiftsoglou, S.A.; Vartanian, T.K.; Brown, R.H., Jr.; Carroll, M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. USA, 2008, 105(46), 17913-17918.
33. Zhang, R.; Gascon, R.; Miller, R.G.; Gelinas, D.F.; Mass, J.; Hadlock, K.; Jin, X.; Reis, J.; Narvaez, A.; McGrath, M.S. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol., 2005, 159(1-2), 215-224.
34. Appel, S.H.; Smith, R.G.; Engelhardt, J.I.; Stefani, E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J. Neurol. Sci., 1993, 118(2), 169-174.
35. Wilms, H.; Sievers, J.; Dengler, R.; Bufler, J.; Deuschl, G.; Lucius, R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J. Neuroimmunol., 2003, 144(1-2), 139-142.
36. Henkel, J.S.; Engelhardt, J.I.; Siklós, L.; Simpson, E.P.; Kim, S.H.; Pan, T.; Goodman, J.C.; Siddique, T.; Beers, D.R.; Appel, S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol., 2004, 55(2), 221-235.
37. Alexianu, M.E.; Kozovska, M.; Appel, S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology, 2001, 57(7), 1282-1289.
38. Mantovani, S.; Gabelli, S.; Pasini, A.; Alimenti, D.; Perotti, C.; Melazzini, M.; Bendotti, C.; Mora, G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol., 2009, 210(1-2), 73-79.
39. Holmøy, T.; Roos, P.M.; Kvale, E. Ø. ALS: Cytokine profile in cerebrospinal fluid T-cell clones. Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler., 2006, 7(3), 183-186.
40. Cereda, C.; Baiocchi, C.; Bongioanni, P.; Cova, E.; Guareschi, S.; Metalli, M.R.; Rossi, B.; Sbalsi, I.; Cuccia, M.C.; Ceroni, M. TNF and sTNFR1/2 plasma levels in ALS patients. J. Neuroimmunol., 2008, 194(1-2), 123-131.
41. Sekizawa, T.; Openshaw, H.; Ohbo, K.; Sugamura, K.; Itoyama, Y.; Niland, J.C. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci., 1998, 154(2), 194-199.
42. Angelov, D.N.; Waibel, S.; Guntinas-Lichius, O.; Lenzen, M.; Neiss, W.F.; Tomov, T.L.; Yoles, E.; Kipnis, J.; Schori, H.; Reuter, A.; Ludolph, A.; Schwartz, M. Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA, 2003, 100(8), 4790-4795.
43. Meininger, V.; Drory, V.E.; Leigh, P.N.;, Ludolph, A.; Robberecht, V.; Silani, V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. Amyotroph Lateral Scler., 2009, 10(5-6), 378-383.
44. Beghi, E.; Chiò, A.; Inghilleri, M.; Mazzini, L.; Micheli, A.; Mora, G.; Poloni, M.; Riva, R.; Serlenga, L.; Testa, D.; Tonali, P. A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology, 2000, 54(2), 469-474.
45. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Tandan, R.; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 2007, 6(12), 1045-1053.
46. Graber, J.J.; Dhib-Jalbut, S. Protective autoimmunity in the nervous system. Pharmacol. Ther., 2009, 121(2), 147-159.